---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045661"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:04:41.070881+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma receives FDA feedback on Phase 3 protocol for MAT2203; meeting set for early Q1 2024

## Summary
- FDA provided written comments on revised Phase 3 protocol for MAT2203 in invasive aspergillosis with limited treatment options.
- Company invited to meeting early Q1 2024 to finalize Phase 3 study design.
- Partnership discussions for MAT2203 remain ongoing.
- Goal is single Phase 3 registration trial for approval.

## SEC filing metadata
- accession: 0001493152-23-045661
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223045661/0001493152-23-045661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223045661/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045661
- JSON: https://secwatch.observer/filing/0001493152-23-045661.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.